Addition of atezolizumab to chemotherapy/bevacizumab shows no PFS benefit in ovarian cancer

The addition of atezolizumab (Tecentriq) to chemotherapy and bevacizumab (Avastin) did not improve outcomes in patients with advanced ovarian cancer compared with chemotherapy and bevacizumab alone, according to data presented at the 2020 ESMO Virtual Congress.

In the phase 3 IMagyn050/GOG 3015/ENGOT-OV39 trial, patients with newly diagnosed stage III/IV ovarian cancer in the intent-to-treat population had overall progression-free survival (PFS) of 19.5 months with the combination treatment compared to 18.4 months with bevacizumab and chemotherapy alone. In a subgroup of patients that were PD-L1–positive (≥1% expression), the median PFS was 20.8 months and 18.5 months, respectively.

Results from an exploratory analysis suggest PFS may be improved with the addition of atezolizumab in patients with PD-L1 immune cell expression ≥5%.

Reference
Moore K, et al. Primary results from IMagynp050/GOG 3015/ENGOT-OV39, a double-blind, placebo-controlled randomized phase 3 trial of bevacizumab-containing therapy +/- atezolizumab for newly diagnosed stage III/IV ovarian cancer. Presented at: 2020 ESMO Virtual Congress.